^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MEGF8 (Multiple EGF Like Domains 8)

    i
    Other names: MEGF8, Multiple EGF Like Domains 8, C19orf49, EGFL4, SBP1, Multiple Epidermal Growth Factor-Like Domains Protein 8, Epidermal Growth Factor-Like Protein 4, EGF-Like-Domain, Multiple 4, FLJ22365, Hepatitis B Virus Pre-S2-Binding Protein 1, EGF-Like Domain-Containing Protein 4, Chromosome 19 Open Reading Frame 49, Multiple EGF-Like Domains Protein 8, HBV Pre S2 Binding Protein 1, HBV Pre-S2-Binding Protein 1, HBV Pre-S2 Binding Protein 1, Multiple EGF-Like-Domains 8, EGF-Like Protein 4, KIAA0817, CRPT2
    Associations

    News

    Trials
    2ms
    MEGF8-driven metabolic reprogramming and immune evasion define a high-risk subtype of endometriosis-associated ovarian cancer. (PubMed, Am J Transl Res)
    This study delineated the molecular-immune landscape of OC, established an 8-gene prognostic model, and identified MEGF8 as a potential therapeutic target. The model predicts responses to immunotherapy and targeted therapies, supporting personalized OC management.
    Journal • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1) • MEGF8 (Multiple EGF Like Domains 8)
    5ms
    Fusion Gene Detection in Driver Mutation-Negative Melanomas Using RNA-Based Anchored Multiplex Polymerase Chain Reaction. (PubMed, Pigment Cell Melanoma Res)
    This Method paper outlines the AMP workflow, including troubleshooting strategies and quality control criteria, and demonstrates its applicability to clinical samples. Our findings support the utility of RNA-based fusion detection in driver-negative melanomas and the potential of fusion genes as actionable targets.
    Journal • Polymerase Chain Reaction • Tumor mutational burden • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • NF1 (Neurofibromin 1) • MAD1L1 (Mitotic Arrest Deficient 1 Like 1) • MEGF8 (Multiple EGF Like Domains 8)
    |
    BRAF mutation • KIT mutation • TMB-L • RAS mutation
    |
    FusionPlex® Dx
    over1year
    RNA-based multiplex polymerase chain reaction and sequencing to detect fusion genes in melanoma (ESMO Asia 2024)
    Conclusions The Archer® FUSIONPlex® custom panel detected fusion genes in 10% of driver gene-negative melanomas. Combining DNA- and RNA-based multiplex sequencing is useful to identify potentially targetable gene alterations.
    Polymerase Chain Reaction • IO biomarker
    |
    NF1 (Neurofibromin 1) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • ETV1 (ETS Variant Transcription Factor 1) • MAD1L1 (Mitotic Arrest Deficient 1 Like 1) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8) • RASGRF1 (Ras Protein Specific Guanine Nucleotide Releasing Factor 1) • MEGF8 (Multiple EGF Like Domains 8) • RASGRF2 (Ras Protein Specific Guanine Nucleotide Releasing Factor 2)
    |
    BRAF mutation • KIT mutation • NF1 mutation • BRAF fusion • CIC deletion
    |
    Archer® FusionPlex® Sarcoma kit • FusionPlex® Dx
    almost2years
    Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. (PubMed, Nat Med)
    PFS24 was associated with presence of MEGF8 or SETD1B somatic mutations. This trial met its co-primary endpoints (ORR and PFS24) early, and our findings highlight several genetic and tumor microenvironment parameters associated with response to PD-1 blockade in dMMR cancers, generating rationale for their validation in larger cohorts.ClinicalTrials.gov identifier: NCT03241745 .
    P2 data • Journal • Mismatch repair • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • SETD1B (SET Domain Containing 1B, Histone Lysine Methyltransferase) • MEGF8 (Multiple EGF Like Domains 8)
    |
    MSI-H/dMMR • MET mutation
    |
    Opdivo (nivolumab)
    over2years
    Genomic Landscape of Osteosarcoma and Undifferentiated Sarcoma of Bone in an Older Patient Population (CAP 2023)
    These results are clinically significant because they show that the genetic signatures in older patients with osteosarcoma and undifferentiated sarcoma are extremely diverse. Further, these results are important because targeted therapies such as DNA damage response (DDR) inhibitors could be an important prospective therapeutic approach in some of these patients.
    Clinical • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MUC16 (Mucin 16, Cell Surface Associated) • NOTCH3 (Notch Receptor 3) • AHNAK2 (AHNAK Nucleoprotein 2) • CSMD3 (CUB And Sushi Multiple Domains 3) • MEGF8 (Multiple EGF Like Domains 8)
    |
    TP53 mutation
    almost3years
    Identification of a ferroptosis- and oxidative stress-associated gene signature for prognostic stratification of ovarian cancer. (PubMed, Am J Transl Res)
    Our novel clustering algorithm was used to create distinct clusters of OC patients and a prognostic model was developed that accurately predicted patient outcomes and chemotherapy responses. This approach offers effective precision medicine for OC patients.
    Journal • Gene Signature
    |
    MEGF8 (Multiple EGF Like Domains 8) • PLXNA1 (Plexin A1)
    over3years
    SPECTRUM OF EWING-LIKE FUSIONS AND SECONDARY GENOMIC ALTERATIONS FROM A LARGE NEXT GENERATION SEQUENCING (NGS) COMPREHENSIVE GENOMIC PROFILING (CGP) DATABASE (CTOS 2022)
    The prevalence of “Ewing-like” sarcoma is low and the spectrum of fusion partners diverse, yet many of these diagnoses may be misclassified without a comprehensive molecular diagnosis. Amplifications in MDM2 and CDK4 are potentially targetable genomic events in this population.
    Next-generation sequencing • Tumor Mutational Burden • MSi-H Biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • WT1 (WT1 Transcription Factor) • CREBBP (CREB binding protein) • BCOR (BCL6 Corepressor) • EWSR1 (EWS RNA Binding Protein 1) • FRS2 (Fibroblast Growth Factor Receptor Substrate 2) • FUS (FUS RNA Binding Protein) • NUTM1 (NUT Midline Carcinoma Family Member 1) • TFCP2 (Transcription Factor CP2) • MEGF8 (Multiple EGF Like Domains 8) • PATZ1 (POZ/BTB And AT Hook Containing Zinc Finger 1)
    |
    MSI-H/dMMR